Background. In PRIMERS-I, the ARLG assessed the performance characteristics of PCR/ESI-MS, molecular beacons (MB), microarrays, and ion torrent sequencing (IT) to detect b-lactam (b-L) resistance in highly drug resistant Escherichia coli (Ec) and Klebsiella pneumoniae (Kp). In PRIMERS-II, PCR/ESI-MS and MB tested in a blinded fashion a heterogeneous collection of Ec and Kp and asked how well these 2 platforms predicted b-L susceptibility (S) or resistance (R).
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Methods. S/R to 14 b-Ls were determined (CLSI) using 196 Ec and Kp isolates.
The probabilities of identifying genetic markers of b-L susceptibility/non-susceptibility based on the absence/presence of bla genes (vs. MIC phenotype as the standard) were estimated using 95% confidence intervals (CIs) for each b-L for each platform. The performance of each platform was compared.
Results. Select estimated probabilities of detecting genotypic susceptibility/non-susceptibility MIC-defined phenotypes are summarized (table). In a community that has a prevalence of 15% ceftazidime resistance and 5% carbapenem resistance, the susceptibility predictive values (SPV) of PLEX-ID and MB are 100%, and 96% for ceftazidime; 100%, and 99% for imipenem. The non-susceptibility predictive values (nSPV) of PLEX-ID and MB are 69%, and 73% for ceftazidime; 41%, and 50% for imipenem. 
